Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.
NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. (PTGX) ("Protagonist" or "the Company") announced today that rusfertide, a potential first-in-class hepcidin-mimetic ...
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced ...
Takeda ( TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...
ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...
Pharmaceutical Technology on MSN
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
The NDA follows positive results from the Phase III global placebo-controlled, randomised VERIFY trial.
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced that clinical data on rusfertide in polycythemia vera, including the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results